Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

References

• Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28(2):75–82.
   PubMed Web of Science ®Google Scholar
• Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29(1):26–48.
   PubMed Web of Science ®Google Scholar
• Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253–3261.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo. Treatment of pain associated with fibromyalgia. Clinicaltrials.gov [NCT02187471]; 2014 [cited 2016 Mar 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02187471?term=DS-5565&rank=1.
   Google Scholar
• Daiichi Sankyo. DS-5565 Phase III study for post-herpetic neuralgia. Clinicaltrials.gov [NCT02318719]; 2014 [cited 2016 Mar 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02318719?intr=mirogabalin&rank=2.
   Google Scholar
• Gee NS, Brown JP, Dissanayake VUK, et al. The novel anticonvulsant drug, gabapentin (neurontin), binds to the subunit of a calcium channel. J Biol Chem. 1996;271(10):5768–5776.
   PubMed Web of Science ®Google Scholar
• Kukkar A, Bali A, Singh N, et al. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36(3):237–251.
   PubMed Web of Science ®Google Scholar
• Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin–calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142(1–2):13–16.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137–150.
   PubMed Web of Science ®Google Scholar
• Davies A, Hendrich J, Van Minh AT, et al. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007;28(5):220–228.
   PubMed Web of Science ®Google Scholar
• Piechan JL, Donevan SD, Taylor CP, et al. Pregabalin, a novel anticonvulsant, analgesic, and anxiolytic drug, exhibits class-specific alpha2—delta-1 and alpha2—delta-2 calcium channel subunit binding. Annual Meeting of Neuroscience; 2004 Nov 9–13; Abstract number 115.11; San Diego, CA.
   Google Scholar
• Yokoyama T, Arakawa N, Domon Y, et al. Pharmacological, pharmacokinetics and safety profiles of DS-5565, a novel α2-δ ligand. J Neurol Sci. 2013;333:e535.
   Google Scholar
• Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011;667(1–3):80–90.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (alpha2-delta) type 1 protein. Neuroscience. 2008;155(2):510–521.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Porreca F, Taylor CP, et al. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013;34(6):332–339.
   PubMed Web of Science ®Google Scholar
• White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85–110.
   PubMed Web of Science ®Google Scholar
• Nasca C, Orlando R, Marchiafava M, et al. Exposure to predator odor and resulting anxiety enhances the expression of the alpha2 delta subunit of voltage-sensitive calcium channels in the amygdala. J Neurochem. 2013;125(5):649–656.
   PubMed Web of Science ®Google Scholar
• Chen C, Cowles VE, Sweeney M. The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. Curr Clin Pharmacol. 2013;8(1):67–72.
   PubMedGoogle Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res. 1992;11(1):45–49.
   PubMed Web of Science ®Google Scholar
• Luer MS, Hamani C, Dujovny M, et al. Saturable transport of gabapentin at the blood-brain barrier. Neurol Res. 1999;21(6):559–562.
   PubMed Web of Science ®Google Scholar
• Gidal BE, Radulovic LL, Kruger S, et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2–3):123–127.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378–1388.
   PubMed Web of Science ®Google Scholar
• Kume A. Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose? Neuropsychiatr Dis Treat. 2014;10:249–262.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Gabapentin-enacarbil [online]; 2012 [cited 2016 May 30]. Available from: http://google2.fda.gov/search?q=gabapentin-enacarbil&client=FDAgov&site=FDAgov‎&proxystylesheet=FDAgov&requiredfields=-archive%3AYes&output=xml_no_dtd&getfields=*.
   Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941–950.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs. 2008;68(15):2205–2223.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol. 2015;29(10):1047–1060.
   PubMed Web of Science ®Google Scholar
• Yamamura N, Yamada M, Takahashi M, et al. Pharmacokinetics of DS-5565, a novel α2-δ ligand, in rats and monkeys and assessment of DDI risk (P7.313). Neurology. 2014;82(1):P7.313.
   Google Scholar
• Yin OQ, Merante D, Truitt K, et al. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol. 2016;56(2):203–212.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo. DS-5565 Phase III study for diabetic peripheral neuropathic pain. Clinicaltrials.gov [NCT02318706]; 2014 [cited 2016 Mar 15]. Available from: https://ClinicalTrials.gov/show/NCT02318706.
   Google Scholar
• Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry. 1987;50(6):682–686.
   PubMed Web of Science ®Google Scholar
• Tyndel F. Interaction of gabapentin with other antiepileptics. Lancet. 1994;343(8909):1363–1364.
   PubMed Web of Science ®Google Scholar
• Sanchez-Romero A, Duran-Quintana JA, Garcia-Delgado R, et al. [Possible gabapentin phenytoin interaction]. Rev Neurol. 2002;34(10):952–953.
   PubMed Web of Science ®Google Scholar
• Hussein G, Troupin AS, Montouris G. Gabapentin interaction with felbamate. Neurology. 1996;47(4):1106.
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498–507.
   PubMed Web of Science ®Google Scholar
• Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91(1):185–191.
   PubMed Web of Science ®Google Scholar
• Yagi T, Naito T, Mino Y, et al. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248–254.
   PubMed Web of Science ®Google Scholar
• Schjerning O, Lykkegaard S, Damkier P, et al. Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives. Pharmacopsychiatry. 2015;48(1):15–18.
   PubMed Web of Science ®Google Scholar
• Pfizer. Lyrica (pregabalin): US prescribing information [online]; 2013 [cited 2016 Mar 15]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561.
   Google Scholar
• Jj E, Sadosky AB, Ten Eyck LL, et al. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia. Clinicoecon Outcomes Res. 2014;6:389–399.
   PubMedGoogle Scholar
• Ellis JJ, Sadosky AB, Ten Eyck LL, et al. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine. BMC Health Serv Res. 2015;15:159.
   PubMed Web of Science ®Google Scholar
• Jansen M, Merante D, Currie A, et al. (391) Coadministration of mirogabalin and lorazepam in healthy subjects: results from a randomized, double-blind, drug-drug interaction study. J Pain. 2015;16(4):S73.
   Google Scholar
• Jansen M, Merante D, Currie A, et al. (390) Coadministration of mirogabalin and ethanol in healthy subjects: results from a randomized, double-blind, drug-drug interaction study. J Pain. 2015;16(4):S73.
   Google Scholar
• Mendell J, Warren V, Dishy V, et al. Pharmacodynamics (PD), pharmacokinetics (PK), safety, and tolerability of mirogabalin when coadministered with tramadol: results from a randomized, double-blind, drug-drug interaction study. 9th Congress of the European Pain Federation (EFIC); 2015 Sep 2–5; Vienna, Austria.
   Google Scholar
• Al-Bachari S, Pulman J, Hutton JL, et al. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013;7:CD001415.
   Google Scholar
• Beydoun A. Monotherapy trials with gabapentin for partial epilepsy. Epilepsia. 1999;40(Suppl 6):S13–6. discussion S73–4
   Google Scholar
• Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–1344.
   PubMed Web of Science ®Google Scholar
• Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;3:CD005612.
   Google Scholar
• Zhou Q, Zheng J, Yu L, et al. Pregabalin monotherapy for epilepsy. Cochrane Database Syst Rev. 2012;10:CD009429.
   PubMedGoogle Scholar
• Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3:CD007076.
   PubMed Web of Science ®Google Scholar
• Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5(1):38–56.
   PubMedGoogle Scholar
• Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639–656.
   PubMed Web of Science ®Google Scholar
• Fuzier R, Serres I, Guitton E, et al. French Network of pharmacovigilance C. Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database. Drug Saf. 2013;36(1):55–62.
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701–1709.
   PubMed Web of Science ®Google Scholar
• Smith TL, Baldwin A, Cunningham LL Jr, et al. Rash associated with pregabalin use. Ann Pharmacother. 2008;42(12):1899–1902.
   PubMed Web of Science ®Google Scholar
• Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012;11(3):487–502.
   PubMed Web of Science ®Google Scholar
• Mula M, Kanner AM, Schmitz B, et al. Antiepileptic drugs and suicidality: an expert consensus statement from the task force on therapeutic strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199–203.
   PubMed Web of Science ®Google Scholar
• Pereira A, Gitlin MJ, Gross RA, et al. Suicidality associated with antiepileptic drugs: implications for the treatment of neuropathic pain and fibromyalgia. Pain. 2013;154(3):345–349.
   PubMed Web of Science ®Google Scholar
• Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401–1409.
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Brown CH, et al. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Saf. 2010;19(12):1241–1247.
   PubMed Web of Science ®Google Scholar
• Harmark L, Puijenbroek E, Grootheest K. Longitudinal monitoring of the safety of drugs by using a web-based system: the case of pregabalin. Pharmacoepidemiol Drug Saf. 2011;20(6):591–597.
   PubMed Web of Science ®Google Scholar
• Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229–233.
   PubMed Web of Science ®Google Scholar
• Carrasco M, Rao SC, Bearer CF, et al. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol. 2015;53(5):445–447.
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335–1342.
   PubMed Web of Science ®Google Scholar
• Schjerning O, Rosenzweig M, Pottegard A, et al. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30(1):9–25.
   PubMed Web of Science ®Google Scholar
• Guttuso T Jr, Shaman M, Thornburg LL. Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;181:280–283.
   PubMed Web of Science ®Google Scholar
• Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016;86(24):2251–2257.
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52(7):1280–1291.
   PubMed Web of Science ®Google Scholar
• Delahoy P, Thompson S, Marschner IC. Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol. 2010;10:104.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
   PubMed Web of Science ®Google Scholar
• Zhang SS, Wu Z, Zhang LC, et al. Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta-analysis. Acta Anaesthesiol Scand. 2015;59(2):147–159.
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5(12):e14433.
   PubMed Web of Science ®Google Scholar
• Mehta S, McIntyre A, Dijkers M, et al. Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis. Arch Phys Med Rehabil. 2014;95(11):2180–2186.
   PubMed Web of Science ®Google Scholar
• Kim JS, Bashford G, Murphy TK, et al. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain. 2011;152(5):1018–1023.
   PubMed Web of Science ®Google Scholar
• Atalay H, Solak Y, Biyik Z, et al. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33(6):401–408.
   PubMed Web of Science ®Google Scholar
• Biyik Z, Solak Y, Atalay H, et al. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. Int Urol Nephrol. 2013;45(3):831–837.
   PubMed Web of Science ®Google Scholar
• Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29(3):177–182.
   PubMed Web of Science ®Google Scholar
• Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):E705–14.
   PubMed Web of Science ®Google Scholar
• Ney JP, Devine EB, Watanabe JH, et al. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med. 2013;14(5):706–719.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943.
   PubMed Web of Science ®Google Scholar
• Merante D, Rosenstock J, Sharma U, et al. Effect of mirogabalin on patient-reported pain and sleep: results from a randomized, double-blind, placebo- and active (pregabalin) comparator-controlled adaptive Phase 2 study. Presented at the 9th Congress of the European Pain Federation (EFIC); 2015 Sep 2–5; Vienna, Austria.
   Google Scholar
• Hutmacher MM, Frame B, Miller R, et al. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol. 2016;56(1):67–77.
   PubMed Web of Science ®Google Scholar
• Uceyler N, Sommer C, Walitt B, et al. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:CD010782.
   PubMed Web of Science ®Google Scholar
• Nuesch E, Hauser W, Bernardy K, et al. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72(6):955–962.
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–521.
   PubMed Web of Science ®Google Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010609.
   PubMed Web of Science ®Google Scholar
• Doleman B, Heinink TP, Read DJ, et al. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. Anaesthesia. 2015;70(10):1186–1204.
   PubMed Web of Science ®Google Scholar
• Achuthan S, Singh I, Varthya SB, et al. Gabapentin prophylaxis for postoperative nausea and vomiting in abdominal surgeries: a quantitative analysis of evidence from randomized controlled clinical trials. Br J Anaesth. 2015;114(4):588–597.
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015;114(1):10–31.
   PubMed Web of Science ®Google Scholar
• Alayed N, Alghanaim N, Tan X, et al. Preemptive use of gabapentin in abdominal hysterectomy: a systematic review and meta-analysis. Obstet Gynecol. 2014;123(6):1221–1229.
   PubMed Web of Science ®Google Scholar
• Hwang SH, Park IJ, Cho YJ, et al. The efficacy of gabapentin/pregabalin in improving pain after tonsillectomy: A meta-analysis. Laryngoscope. 2016;126(2):357–366.
   PubMed Web of Science ®Google Scholar
• Park IJ, Kim G, Ko G, et al. Does preoperative administration of gabapentin/pregabalin improve postoperative nasal surgery pain? Laryngoscope. 2016. [Epub ahead of print].
   Google Scholar
• Yu L, Ran B, Li M, et al. Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis. Spine (Phila Pa 1976). 2013;38(22):1947–1952.
   PubMed Web of Science ®Google Scholar
• Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg. 2012;115(2):428–442.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013;7:CD008307.
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, Moore RA, et al. Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database Syst Rev. 2010;5:CD008183.
   PubMed Web of Science ®Google Scholar
• Mkontwana N, Novikova N. Oral analgesia for relieving post-caesarean pain. Cochrane Database Syst Rev. 2015;3:CD010450.
   Google Scholar
• Ghai A, Gupta M, Hooda S, et al. A randomized controlled trial to compare pregabalin with gabapentin for postoperative pain in abdominal hysterectomy. Saudi J Anaesth. 2011;5(3):252–257.
   PubMedGoogle Scholar
• Khurana G, Jindal P, Sharma JP, et al. Postoperative pain and long-term functional outcome after administration of gabapentin and pregabalin in patients undergoing spinal surgery. Spine (Phila Pa 1976). 2014;39(6):E363–8.
   Google Scholar
• Ozgencil E, Yalcin S, Tuna H, et al. Perioperative administration of gabapentin 1,200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study. Singapore Med J. 2011;52(12):883–889.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barre syndrome. Cochrane Database Syst Rev. 2015;4:CD009950.
   PubMedGoogle Scholar
• Cheong YC, Smotra G, Williams AC. Non-surgical interventions for the management of chronic pelvic pain. Cochrane Database Syst Rev. 2014;3:CD008797.
   PubMed Web of Science ®Google Scholar
• Pinto RZ, Maher CG, Ferreira ML, et al. Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ. 2012;344:e497.
   PubMed Web of Science ®Google Scholar
• Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev. 2011;12:CD006380.
   PubMed Web of Science ®Google Scholar
• Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry. 2011;56(9):558–566.
   PubMed Web of Science ®Google Scholar
• Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199.
   PubMed Web of Science ®Google Scholar
• Samuel M, Zimovetz EA, Gabriel Z, et al. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol. 2011;26(2):63–68.
   PubMed Web of Science ®Google Scholar
• Hornyak M, Scholz H, Kohnen R, et al. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev. 2014;18(2):153–164.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults–an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–1062.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Gabapentin enacarbil: in patients with restless legs syndrome. CNS Drugs. 2012;26(12):1073–1083.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Cinquini M, Amato L, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2015;4:CD006754.
   Google Scholar
• Marshall K, Gowing L, Ali R, et al. Pharmacotherapies for cannabis dependence. In: Cochrane Database Syst Rev. 2014;12:CD008940.
   PubMed Web of Science ®Google Scholar
• Pani PP, Trogu E, Pacini M, et al. Anticonvulsants for alcohol dependence. In: Cochrane Database Syst Rev. 2014;2:CD008544.
   PubMed Web of Science ®Google Scholar
• Siemens W, Xander C, Meerpohl JJ, et al. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int. 2014;111(50):863–870.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Tzellos T, Kouvelas D, et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther. 2009;31(2):221–235.
   PubMed Web of Science ®Google Scholar
• Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–1589.
   PubMed Web of Science ®Google Scholar
• Hoekstra CE, Rynja SP, Van Zanten GA, et al. Anticonvulsants for tinnitus. Cochrane Database Syst Rev. 2011;7:CD007960.
   Google Scholar
• Wadman RI, Bosboom WM, Van Der Pol WL, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2012;4:CD006282.
   PubMed Web of Science ®Google Scholar
• Thompson DF, Brooks KG. Gabapentin therapy of hiccups. Ann Pharmacother. 2013;47(6):897–903.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Arakawa N, Domon Y, et al. Pharmacological, pharmacokinetics and safety profiles of DS-5565, a novel α2δ ligand. Neurology. 2014;82(10Supplement):P7.301.
   PubMed Web of Science ®Google Scholar